HOME >> BIOLOGY >> NEWS
Heart has enough oxygen to survive hypothermia, CPR crucial

ic groups and a control group. They exposed one hypothermic group to 15C (59F) for one hour before rewarming. They exposed the second group to 15C, but for five hours. The control group was kept at normal temperature, 37C (98.6F). The researchers followed the hemodynamic changes during hypothermia and rewarming and later examined the rats' heart cells.

When core body temperature was lowered to 15C, both hypothermic groups experienced a similar reduction in circulating blood volume. And both showed that the physiological mechanisms that help transport oxygen and help unload oxygen from hemoglobin were working. "As a consequence, oxygen supply was not a limiting factor for survival in the present experiments," the authors wrote.

The rats in the one-hour group spontaneously normalized their blood pressure, cardiac output and heart rate after they were rewarmed, Tveita noted. However, the rats in the five-hour group, which were significantly more likely to experience heart failure during rewarming, experienced substantial lowering of cardiac output and other cardiac functions.

"We conclude that the heart failure we see after rewarming is not due to a lack of oxygen supply or oxygen transportation because unloading of oxygen at the cell level from hemoglobin is functioning," Tveita stated. Thus, it appears that the problem comes as a result of the lower cardiac output, he added.

"Thus, efforts aimed at elevating cardiac output in this phase seem advisable in order to optimize oxygen supply, reperfuse (restore blood flow to) vascular beds (minute blood vessels) and prevent rewarming shock formation," the authors wrote

Source and funding

"Is oxygen supply a limiting factor for survival during rewarming from profound hypothermia?" by Timofei V. Kondratiev, Kristina Flemming, and Mikhail A. Sovershaev, University of Troms, Norway; Eivind S.P. Myhre, Srlandet Hospital, Kristiansand; and Torkjel Tveita, Univer
'"/>

Contact: Christine Guilfoy
cguilfoy@the-aps.org
301-634-7253
American Physiological Society
18-Jul-2006


Page: 1 2 3 4

Related biology news :

1. Hearts of male and female rainbow trout are different
2. Heart failure: Intervention possibilities from imaging programmed cell loss
3. Heart intervention doesnt outweigh medicine in study
4. International Society for Heart and Lung Transplantation 27th Annual Meeting and Scientific Sessions
5. Heart rhythm genes possible factors in SIDS
6. Hearts or tails?
7. Heart smart: new drug improves blood flow
8. Defusing a time bomb: Heart attack risk-detection technology developed at UH
9. Heart failure wall stress drops 38% with moderate thyroid hormone therapy
10. New studies released at the Heart Rhythm Societys Annual Meeting
11. Molecular testing impact: Heart transplant patients benefit from new technology, easier monitoring

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Heart has enough oxygen survive hypothermia CPR crucial

(Date:5/10/2015)... , May 11, 2015 Fingerprint ... sensors FPC1025 and FPC1155 from the distributor World Peace Industrial ... FPC,s distributors in Asia . Deliveries are ... will be used by smartphone manufacturers in China ... in the communicated revenue guidance of + 1 000 MSEK for ...
(Date:5/7/2015)... May 7, 2015 Fingerprint ... FPC1022 and FPC1035, FPC,s smallest touch fingerprint sensors ... mainly considered for integration on the backside of ... OEMs increased possibilities to integrate touch fingerprint sensors ... also improves possibilities for module manufacturers to customize ...
(Date:5/5/2015)... 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, reminds investors and media that  Mr. ... presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of ... themed Global Fraud: Where is the Trust in Cyberspace? ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
(Date:5/21/2015)... LOS ANGELES , May 21, 2015 /PRNewswire/ ... research and development company specializing in oncology, today ... 2 clinical trial with aldoxorubicin for the treatment ... of brain cancer.  The open-label, multisite trial is ... of aldoxorubicin in patients whose tumors have progressed ...
(Date:5/21/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: RP) ... focused on the development of autologous cell therapies, ... International Society for Cellular Therapy (ISCT) on RepliCel,s ... in a Phase 1/2 clinical trial.  The presentation, ... 5:30 PM to 7:00 PM local time, will ...
(Date:5/20/2015)... 20, 2015 Veracyte, Inc . ... demonstrating the ability of the company,s molecular classifier ... other interstitial lung diseases (ILDs) using samples obtained ... to help thousands of patients avoid invasive, risky ... diagnosis – a frequent challenge for physicians and ...
(Date:5/20/2015)... and Markets ( http://www.researchandmarkets.com/research/qfxkcq/global_cell ) has announced ... Outlook 2020 " report to their offering. ... medicine is expected to have huge marketing potential. Presently, ... the growth of deregulated organs. Several therapeutic molecules are ... form new tissue or sometimes organ transplant is required. ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3
Cached News: